Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by a defect of phagocytic cells that renders them incapable of producing reactive oxygen metabolites required for microbial killing, most commonly due to mutations of the cytochrome b-245 beta polypeptide (CYBB; MIM# 300481).
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Recurrent life-threatening bacterial and fungal infections and granulomata formation are the hallmarks of this disorder. The prognosis is dismal unless continued antimicrobial prophylaxis is instituted early on, which may limit infectious complications. 2, 3 A potentially curative approach is allogeneic hematopoietic SCT (HSCT), as shown by several groups. 4, 5 This therapy, however, has so far only been applied successfully in patients with available HLA-compatible donors, including 9/10 and 10/10 HLA-matched related and unrelated donor transplants as well as 4/6 and 5/6 unrelated cord transplants. 6 In a single case report of an HLAhaploidentical HSCT following reduced intensity conditioning, the patient had a secondary graft failure and required a second successful transplant using an unrelated cord blood graft (5/6 match). 7 Here we report the first successful HLA-haploidentical SCT in CGD, which indicates the possibility of a broader application of SCT in patients lacking alternative therapeutic options.
The patient was diagnosed at the age of 6 weeks because of a positive family history for CGD. A previously described hemizygous mutation in CYBB was identified (c.321insG; p. Ile108Aspfs*15). 8 The patient had no detectable NADPH-oxidase activity in the dihydrorhodamine and the nitroblue terazolium test. McLeod phenotype was formally excluded by a normal expression of Kell-antigens on red cells. In spite of early and continued antimicrobial prophylaxis (cotrimoxazole, itraconazole) the patient developed severe complications including recurrent lymph node abscesses, recurrent airway infections resulting in chronic pulmonary disease, as well as chronic inflammatory bowel disease. At the age of 6 years a therapeutic attempt with subcutaneous γ-IFN was started. Despite this treatment he developed osteomyelitis of his right fourth rib, with surrounding soft and pulmonary tissue involved at the age of 10 years. Both Aspergillus terreus and Staphylococcus aureus were identified in tissue cultures obtained from the partially resected rib. Despite an intensive postoperative antimicrobial regimen over the following 4 months, using combinations of teicoplanin, meropenem, ciprofloxacin, liposomal amphotericine B and voriconazole, and continuation of subcutaneous γ-IFN the patient failed to clear this focus. An F18DG-PET-CT continued to reveal an active inflammatory process at the resection site of the rib as well as pulmonary infiltrations ( Figure 1 ). In addition, the patient suffered from severe failure to thrive (body weight 7 kg below 3rd percentile) in spite of prolonged parenteral nutrition. Since the patient suffered from an intractable infection with dismal prognosis and no related or unrelated (9/10 or 10/10) HLA-compatible donor was available, the possibility of a haploidentical SCT was discussed with the parents and the patient. After written parental consent, a complete removal of the fourth rib including resection of the adjacent upper lobe of the right lung was performed before conditioning. Histology revealed active fungal osteomyelitis and pulmonary infection with vital hyphae. Three months after surgery the patient received conditioning consisting of a combination of BU (Busulfex) at 176 mg/kg over 4 days (three times daily administration) without drug monitoring according to weight-based recommendations, followed by fludarabine at 150 mg/m 2 over 5 days and thiothepa at 10 mg/kg on one day. In addition, alemtuzumab was given at a total dose of 1 mg/kg over 5 consecutive days (see Figure 2 ). Voriconazole was stopped 1 week before conditioning. The father was the preferred HLA-haploidentical donor because of the carrier status of the mother. PBSCs from the HLAhaploidentical father (5/10 mismatch) were harvested after G-CSF stimulation (11 μg/kg/day over 5 days) and were transfused after positive selection of CD34+ cells (CliniMACS-LS, Miltenyi Biotec, Bergisch Gladbach, Germany) followed by further depletion of T cells by anti-CD3 monoclonal antibodies (Dynabeads, Invitrogen, Darmstadt, Germany; OKT-3 antibodies, Janssen-Cilag, Neuss, Germany). The number of infused CD34+ cells was 1.0 × 10 7 /kg and of CD3+ cells was 0.8 × 10 4 /kg. Granulocyte transfusions from unrelated donors were infused every other day from day 0 to day +11. In addition, the patient received antibiotic prophylaxis using teicoplanin and ciprofloxacin during aplasia, as well as antimykotic therapy using caspofungin during conditioning and aplasia. No serious bacterial infections occurred. The patient developed mucositis grade 3 and was given total parenteral nutrition for 2 weeks. Aplasia (WBC o200/μL) started on day 0 and lasted until day +13. Hematological reconstitution was prompt, with neutrophils 4500/μL on day +16 (Figure 2 ) and platelets 420 000 on day +33. He was transfused with 14 units of platelets and 8 units of packed red cells. Red cell reconstitution was delayed for several months, likely due to blood group incompatibility (donor ARh+, recipient 0Rh+). No signs of GVHD developed. The recipient (and the donor) was IgG positive for CMV and EBV, but no reactivation of these or other viruses developed. T-cell numbers (CD3+) remained below 500/μL during the first year and subsequently normalized completely, including normal numbers of naive CD4+ T cells. After discontinuation of Ig substitution at 9 months and triple immunization, antibody titers were found positive for tetanus, diphtheria, Haemophilus influenzae B and pneumococci. Chimerism was evaluated repetitively and revealed sustained donor cell engraftment. In the most recent evaluation 4 years after HSCT, 90% of peripheral blood nucleated cells (short tandem repeat analysis) as well as red cells (flow cytometry) were of donor type. Starting on day +18, cotrimoxazole was given at 5 mg/kg (trimethoprime) 3 × /week for PCP-prophylaxis and was stopped after 12 months. On day +28, ciprofloxacin was replaced by cefuroxime, which was given for 9 months as prophylactic antibiotic agent because of chronic pulmonary disease of the patient with bronchiectasis. Posaconazole was started at discharge on day +58 replacing caspofungin as antifungal agent, and was continued until 12 months after HSCT. Throughout the follow-up period of 4 years no serious infections have occurred. The patient, now 15 years of age, is attending school regularly and is able to participate in sports without significant restrictions. Inflammatory bowel disease resolved completely after transplantation; however, skeletal age remains 2 years behind the chronological age and the patient has not crossed the percentiles for height and weight. No primary or secondary endocrinological dysfunction was identified.
In contrast to the patient mentioned above 7 who experienced graft failure following reduced-intensity conditioning, engraftment in our patient was sustained and included both lymphoid and myeloid lineages. This experience indicates the importance of myeloablative conditioning in order to avoid graft rejection and to ensure long-term myeloid engraftment in CGD following T-celldepleted, HLA-haploidentical HSCT. The considerable delay in the T-cell reconstitution, which is typically observed in patients undergoing T-cell-depleted, HLA-haploidentical HSCT, poses a considerable threat of developing viral infections. The fact that patients with CGD are not at increased risk for chronic viral infections prior to transplantation, in contrast to patients with primary T-cell immunodeficiencies, might be an important aspect for the risk-benefit ratio of HLA-haploidentical transplantation for CGD. The most important factor to cure a patient with CGD from refractory fungal disease is the establishment of normal neutrophil functions. This was achieved without delay by the approach described here. Our experience demonstrates that HLA-haploidentical transplantation can be a curative therapeutic option in CGD patients with uncontrolled infections lacking therapeutic alternatives. Figure 2 . After a conditioning regimen consisting of thiotepa 10 mg/kg on one day, intravenous BU 17.6 mg/kg over 4 days, followed by fludarabine at 150 mg/m 2 over 5 days, a total of 6 granulocyte transfusions were administered between day 0 and +11 until neutrophil engraftment developed. G-CSF (5 μg/kg) was administered until day +40 to keep neutrophil numbers 41000/μL.
